Actelion (VTX:ATLN) and Johnson & Johnson (NYSE:JNJ) have re-entered talks to reach a takeover deal, after the US healthcare giant reportedly abandoned its efforts last week. Some suggest that this could mean the end of Sanofi‘s (NYSE:SNY) attempt to make a deal with the Swiss biotech firm, according to Reuters.
J&J and Actelion had been engaged in informal talks for nearly 2 months and J&J had made an offer valued at 250 Swiss francs per share before the company backed out. Actelion has a market value of 23.2 billion Swiss francs, nearly $23 billion USD. ATLN shares were trading at 215 Swiss francs per share in afternoon trading activity today, up 6.5%.
Get the full story at our sister site, Drug Delivery Business News.
The post Actelion, J&J re-enter takeover negotations appeared first on MassDevice.